The NanoDendrix™ platform has so far yielded two early stage oncology assets.
GLY-100 NanoDendrix-poly(I:C) nanoparticles target TLR3 and stimulate a strong innate immune response in cancer and immune cells. Exploring combination therapy in solid tumors starting with Ovarian cancer.
GLY-200 NanoDendrix™ particles carrying cytotoxic payloads and ligands that bind cancer cell surface receptors. Therapeutic potential in various solid tumor indications.